Enteric Fever (Typhoid Fever) Treatment

1. Antibiotic Therapy

First-line options (uncomplicated disease)

• Fluoroquinolones - ciprofloxacin 500 mg orally twice daily for 7-14 days (or 400 mg IV until oral therapy can be started). Agent of choice where susceptibility is preserved, but resistance is now widespread in South Asia, so these are less reliable empirically for travel-associated cases.
• Ceftriaxone - 2 g every 12-24 hours IV/IM for adults (75 mg/kg/day in children) for 7-14 days; cures about 95% of patients, though defervescence can be slower than with fluoroquinolones. This is a mainstay where fluoroquinolone resistance is common - though ceftriaxone-resistant (XDR) outbreaks are now emerging in South Asia.
• Azithromycin - 500 mg/day orally for 7 days (or a 1 g loading dose on day 1 followed by 500 mg daily) is effective for uncomplicated typhoid, including MDR and many XDR strains, and is attractive where oral, low-cost therapy is needed. A 2024 systematic review of RCTs supports oral azithromycin as comparably or more effective than other oral regimens for uncomplicated typhoid across age groups (Uzair et al., 2024, PMID 39623850).

Severe or XDR disease

• Meropenem 1 g IV every 8 hours for 7-14 days (or ~20 mg/kg three times daily) for severe disease due to XDR S. Typhi. Case reports suggest adding azithromycin if response to a carbapenem alone is inadequate (CDC Yellow Book, 2024).

If susceptibility is confirmed

• Ampicillin 25 mg/kg IV every 6 hours, chloramphenicol 50 mg/kg/day (oral or IV, divided into 4 doses), or trimethoprim-sulfamethoxazole 4/20 mg/kg every 12 hours, for 7-14 days - only if the isolate is shown to be susceptible, since resistance to these older agents is now widespread globally.

2. Duration and Response

• Temperature typically normalizes after 3-5 days of effective therapy (may take longer with cephalosporins than fluoroquinolones).
• If fever persists beyond 5 days, evaluate for a persistent focus of infection or resistant organism and adjust therapy based on susceptibility results.

3. Adjunctive/Supportive Care

• IV fluids, correction of electrolyte and acid-base disturbances.
• Blood transfusion if significant intestinal bleeding occurs.
• Intestinal perforation: obtain abdominal imaging if suspected; proceed to laparotomy promptly if perforation is likely, and broaden antimicrobial coverage to include bowel flora.
• Severe disease with coma, delirium, or shock: dexamethasone (3 mg/kg initial dose, then 1 mg/kg every 6 hours for 48 hours) reduces mortality in this subset, but can mask signs of perforation, so should not be continued beyond 48 hours.
• Avoid salicylates.

Recent Evidence Check

Latest WHO/CDC Guidance on Enteric Fever (Typhoid/Paratyphoid) Management

Bottom line

CDC Clinical Guidance (current, 2025)

Empiric treatment — now travel-history-driven

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) infection

• Established resistance to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole means these are now only "alternative" agents, used only when susceptibility is confirmed.
• MDR prevalence: ~9% of isolates in South Asia (2015-2018) vs. 36-59% in parts of Africa (2010-2014).
• XDR Typhi (resistant to ampicillin, ceftriaxone, chloramphenicol, ciprofloxacin, and trimethoprim-sulfamethoxazole) has caused >120 documented U.S. infections through 2023, including 12 in patients with no international travel. Ceftriaxone resistance has also been identified in isolates from travelers returning from Iraq, India, and Afghanistan, and azithromycin resistance has emerged in Bangladesh, Cambodia, India, Nepal, Pakistan, Saudi Arabia, and the U.S.
• For XDR infections not responding to a carbapenem alone, CDC notes case reports suggesting benefit from adding azithromycin.

Monitoring response

• Fever typically persists 3-5 days even with effective therapy (patients may feel worse initially); defervescence is slower with cephalosporins than fluoroquinolones.
• If fever hasn't resolved within 5 days, consider switching antibiotics or searching for a persistent focus of infection (e.g., abscess).

Diagnosis note (relevant to management)

WHO Guidance (prevention-focused, not a treatment protocol)

• 2018 WHO position paper (replacing a 2008 version) formally recommends preferential programmatic use of typhoid conjugate vaccine (TCV) for all ages, prioritizing countries with the highest disease burden or highest rates of drug-resistant typhoid, alongside water/sanitation/hygiene (WASH) improvements.
• WHO has since prequalified four TCV products (Typbar TCV, TYPHIBEV, and in 2024 two more — SkyTyphoid and ZyVac TCV), expanding supply for low- and middle-income countries.
• WHO's older 2003 "Background Document: Diagnosis, Treatment and Prevention of Typhoid Fever" is the closest thing to treatment guidance but is not regularly updated formal policy; it identifies appropriate antibiotics as the standard treatment and flags resistance as a growing concern. During active outbreaks, WHO works with national governments to issue outbreak-specific antibiotic guidance rather than a standing global antibiotic protocol.
• Current WHO messaging (2024-2025 fact sheet) emphasizes that expanding TCV use is expected to reduce antibiotic use and slow further resistance development in Salmonella Typhi, reflecting WHO's strategic framing of the resistance problem as a prevention issue rather than a treatment-protocol issue.

Practical takeaway